Foresite Capital Management Iii, LLC Arcus Biosciences, Inc. Transaction History

Foresite Capital Management Iii, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$6.44 - $10.18 $8.8 Million - $13.9 Million	-1,366,973 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$8.95 - $12.49 $5.92 Million - $8.27 Million	-661,903 Reduced 32.62%	1,366,973 $17.1 Million
Q4 2018 Feb 13, 2019	SELL	$9.74 - $14.5 $13.8 Million - $20.5 Million	-1,416,585 Reduced 41.11%	2,028,876 $21.9 Million
Q1 2018 May 15, 2018	BUY	$15.44 - $17.71 $53.2 Million - $61 Million	3,445,461 New	3,445,461 $42.1 Million

203

48.8M

173K

151K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.15B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Iii, LLC with notifications on news.